Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity

A method of treating a mammal suffering from a disease or condition involving monoamine reuptake or a monoamine receptor related disorder comprising administering to said mammal a therapeutically effective amount of a compound having structural Formula 1

• or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein:
• R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, and R18 are independently selected from the group consisting of hydrogen and deuterium;
• R19, R20, and R21 are independently selected from the group consisting of —CH3 and —CD3;
• provided that said compound of Formula 1 contains at least one deuterium atom;
• and
• provided that deuterium enrichment in said compound of Formula 1 is at least about 1%.

A method of treating a mammal for a drug addiction comprising co-administering a first component and a second component, wherein said first component comprises a therapeutically effective amount of a compound of Formula 1, and said second component comprises a therapeutically effective amount of an opioid antagonist, said compound having structural Formula 1

• or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein:
• R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, and R18 are independently selected from the group consisting of hydrogen and deuterium;
• R19, R20, and R21 are independently selected from the group consisting of —CH3, and —CD3;
• provided that said compound of Formula 1 contains at least one deuterium atom;
• and
• provided that deuterium enrichment in said compound of Formula 1 is at least about 1%.